SLC5A2 and type 2 diabetes mellitus: Several studies in preclinical rodent models of established T2DM have shown that SGLT2 inhibitors could improve endothelial function [20–23], reduce myocardial fibrosis, and enhance systolic and diastolic function [24–26].